391 related articles for article (PubMed ID: 33811620)
1. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
3. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.
Kocael A; Eronat AP; Tüzüner MB; Ekmekçi A; Orhan AL; İkizceli İ; Yılmaz-Aydoğan H; Öztürk O
Mol Biol Rep; 2019 Apr; 46(2):1825-1833. PubMed ID: 30712247
[TBL] [Abstract][Full Text] [Related]
4. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
6. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
8. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
9. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
11. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
[TBL] [Abstract][Full Text] [Related]
12. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
14. Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.
Kim KA; Song WG; Lee HM; Joo HJ; Park JY
Mol Biol Rep; 2014 Nov; 41(11):7305-12. PubMed ID: 25069408
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.
Hirai K; Hayashi H; Ono Y; Izumiya K; Tanaka M; Suzuki T; Sakamoto T; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):132-7. PubMed ID: 22892446
[TBL] [Abstract][Full Text] [Related]
16. Effect of gene polymorphims on the warfarin treatment at initial stage.
Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
[TBL] [Abstract][Full Text] [Related]
17. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
Zhuang W; Wu D; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
[TBL] [Abstract][Full Text] [Related]
18. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
19. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
[TBL] [Abstract][Full Text] [Related]
20. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
